15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Xenon Pharmaceuticals Inc, 10 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $55.00 to $97.00, a moderate spread. The average target of $74.90 sits 15% above the current $64.95. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.19 next quarter toward $-5.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy00%
Buy10100%
Hold00%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Xenon Pharmaceuticals Inc.
As of Jul, 10 of 10 firms rate XENE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
XENE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.19
Range $-1.63 – $-0.95 · 14 analysts · +4% YoY
Next period, 14 analysts expect Xenon Pharmaceuticals Inc to earn $-1.19 a share (range $-1.63 – $-0.95), versus $-1.15 a year earlier. Full-year consensus is $-4.81, growing to $-5.03 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 14 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $2.1M, rising to $33.3M next year.
Top analysts covering Xenon Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XENE.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$90.00+38.6% to target
Overall win rate
52%
+ Follow
#2
Serge Belanger
Needham · Rank #83
Buy
$78.00+20.1% to target
Overall win rate
48%
+ Follow
#3
Laura Chico
Wedbush · Rank #122
Buy
$63.00-3.0% to target
Overall win rate
40%
+ Follow
#4
Jason Gerberry
B of A Securities · Rank #136
Buy
$77.00+18.6% to target
Overall win rate
46%
+ Follow
#5
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
$74.00+13.9% to target
Overall win rate
35%
+ Follow
XENE stock forecast FAQ
What is XENE's average 12-month price target?+
The 10 analysts with a live target average $74.90 for Xenon Pharmaceuticals Inc over the next 12 months, ranging from a $97.00 high to a $55.00 low.
Is XENE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 10 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for XENE?+
The Street-high target is $97.00 (Baird), and the Street-low is $55.00 (Chardan Capital). The average of all 10 active targets is $74.90.
How many Wall Street analysts cover XENE?+
10 analysts have an active rating on Xenon Pharmaceuticals Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering XENE?+
Among analysts who currently cover XENE, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $90.00 target.
What is Xenon Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.19 per share (range $-1.63 – $-0.95) across 14 analysts. Full-year EPS is projected at $-4.81, rising to $-5.03 the following year.
How much revenue is Xenon Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $2.1M, growing to $33.3M next year.
Have analysts been upgrading or downgrading XENE lately?+
As of Jul, 10 of 10 firms rate XENE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XENE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
